Table 1. Clinicopathological characteristics of the 30 HBV-related HCC patients enrolled in this study.
| Characteristicsa | No. of Patients | Median (Range) |
|---|---|---|
| Age (years) | 30 | 54 (28−78) |
| Gender (men/women) | 26/4 | |
| Smoking (yes/no) | 10/20 | |
| Alcohol (yes/no) | 7/23 | |
| HBsAg (positive/negative/NA) | 27/0/3 | |
| HBeAg (positive/negative) | 4/26 | |
| HBV genotype (B/C) | 24/6 | |
| HBV DNA (copies/mL) (20−1.7×108/<20/NA)b | 20/2/8 | 6.8×104 (30.1−1.5×108) |
| Albumin (g/dL) | 30 | 3.7 (2.4−4.9) |
| AST (U/L) | 30 | 53.5 (14.0−290.0) |
| ALT (U/L) | 29 | 56 (13−292) |
| AFP (ng/mL) (≤54000/>54000)c | 26/4 | 35.7 (2.4−4550.0) |
| Tumor size (cm) | 29 | 4.0 (1.5−35.0) |
| Tumor encapsulation (yes/no) | 22/7 | |
| Lymph node involvement (yes/no) | 4/26 | |
| Portal vein thrombosis (yes/no) | 0/30 | |
| Satellite nodule (yes/no) | 6/24 | |
| Vascular invasion (yes/no) | 14/16 | |
| Distant metastasis (yes/no) | 3/27 | |
| Steatosis grade (0/1/2/3) | 18/5/0/0 | |
| Metavir inflammation score (0/1/2/3) | 5/19/1/0 | |
| Ishak fibrosis score (0/1/2/3/4/5/6) | 1/5/5/8/5/1/4 | |
| Child-Pugh cirrhosis score (A/B/C) | 21/6/2 | |
| CLIP score (0/1/2/3/4/5/6) | 10/11/5/2/1/0/0 | |
| BCLC stage (A/B/C/D) | 18/6/4/2 | |
| AJCC TNM stage (I/II/IIIA/IIIB/IIIC/IVA/IVB) | 11/12/3/0/3/0/1 |
aOnly patients with available data were analyzed.
bHBV DNA was measured with a range of 20 to 1.7×108 copies/mL.
cAFP was measured with the highest detection limit of 54000 ng/mL.
Abbreviations: HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HBsAg; hepatitis B surface antigen; NA, not available; HBeAg, hepatitis B e antigen; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFP, alpha-fetoprotein; CLIP, Cancer of the Liver Italian Program; BCLC, Barcelona Clinic Liver Cancer; AJCC, American Joint Committee on Cancer; TNM, tumor-node-metastasis.